Arbutus Biopharma Corp
ABUS
Rank in Stocks
#9490
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company,... Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Share Price
$4.05
Last synced: 2026-11-17
Market Cap
$804.65M
Change (1 day)
0.25%
Change (1 year)
-3.57%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Arbutus Biopharma Corp (ABUS)
Category
Healthcare
P/S ratio for Arbutus Biopharma Corp (ABUS)
P/S ratio as of November 2026 TTM: 3.45
According to Arbutus Biopharma Corp's latest financial reports and stock price, its current price-to-sales ratio (TTM) is 3.45. At the end of 2025 the company had a P/S ratio of 65.44.
P/S ratio history for Arbutus Biopharma Corp from 2000 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.45 | -94.72% |
| 2025 | 65.44 | -33.46% |
| 2024 | 98.35 | 330.04% |
| 2023 | 22.87 | 153.75% |
| 2022 | 9.01 | -76.04% |
| 2021 | 37.61 | -3.40% |
| 2020 | 38.94 | 47.46% |
| 2019 | 26.40 | -26.45% |
| 2018 | 35.90 | 39.07% |
| 2017 | 25.81 | -70.21% |
| 2016 | 86.65 | 965.70% |
| 2015 | 8.13 | -62.69% |
| 2014 | 21.79 | 176.61% |
| 2013 | 7.88 | 64.07% |
| 2012 | 4.80 | 361.12% |
| 2011 | 1.04 | -54.22% |
| 2010 | 2.27 | -34.01% |
| 2009 | 3.45 | 182.32% |
| 2008 | 1.22 | -10.42% |
| 2007 | 1.36 | -23.69% |
| 2006 | 1.79 | -51.15% |
| 2005 | 3.66 | -8.33% |
| 2004 | 3.99 | -75.72% |
| 2003 | 16.43 | 101.41% |
| 2002 | 8.16 | -11.66% |
| 2001 | 9.23 | -47.42% |
| 2000 | 17.56 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 18.29 | 429.30% |
US
|
|
| 10.51 | 204.33% |
US
|
|
| 35.79 | 936.13% |
US
|
|
| 4.19 | 21.28% |
AU
|
|
| 6.63 | 91.98% |
BE
|
Questions about Arbutus Biopharma Corp's P/S ratio
What is Arbutus Biopharma Corp's P/S ratio?
Arbutus Biopharma Corp's P/S ratio is 3.45, as of Nov 2026.
What was Arbutus Biopharma Corp's P/S ratio in 2025?
In 2025, Arbutus Biopharma Corp's P/S ratio was 65.44, compared with 98.35 in 2024.
How has Arbutus Biopharma Corp's P/S ratio changed since 2020?
From 2020 to 2025, Arbutus Biopharma Corp's P/S ratio was highest in 2024 (98.35) and lowest in 2022 (9.01).
How does Arbutus Biopharma Corp's P/S ratio compare with similar companies?
Arbutus Biopharma Corp's P/S ratio (3.45) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.